StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study
Public ClinicalTrials.gov record NCT02082054. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-Blind, Parallel-Group, Dose-Ranging Study Evaluating Safety/ Efficacy Atropine Doses With Pseudoephedrine and Chlorpheniramine in SAR Patients 12 Years of Age and Older
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This active vs active comparative trial will evaluate the safety and efficacy of incremental doses of atropine in combination with pseudoephedrine 120 mg/chlorpheniramine 8 mg in adult patients with a history of seasonal allergic rhinitis. Hypotheses are defined by total nasal symptom scores (TNSS) recorded by subjects in diaries where efficacy will be established by statistical significance where p \< 0.05.
Study identification
- NCT ID
- NCT02082054
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 125 participants
Conditions and interventions
Conditions
Interventions
- PSE 120 mg, CM 8 mg, Atr 0.36 mg Drug
- PSE 120 mg, CM 8 mg, Atr 0.24 mg Drug
- PSE 120 mg, CM 8 mg, Atr 0.12 mg Drug
- PSE 120 mg, CM 8 mg Drug
- Atropine 0.24 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2014 (Type not available)
- Primary completion
- May 2014 (Estimated)
- Completion
- May 2014 (Estimated)
- Last update posted
- May 30, 2014
2014
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Atlanta | Stockbridge | Georgia | 30281 | — |
| Family Allergy and Asthma Institute | Louisville | Kentucky | 40215 | — |
| National Allergy, Asthma & Urticaria Centers of Charleston, PA | Charleston | South Carolina | 29406 | — |
| Central Texas Health Research | New Braunfels | Texas | 78130 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02082054, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 30, 2014 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02082054 live on ClinicalTrials.gov.